Psychedelics
March 23, 2021 08:30 AM Eastern Daylight Time OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license that will allow the Company to conduct research […]
Optimi Health Large Scale Multi-Purpose Mushroom Facility Advances Towards Completion and Licensing
Company on-track for Q3 planting with 50-day window to initial harvest VANCOUVER, BC (GLOBE NEWSWIRE – March 23, 2021) — Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to provide the following overview and update of its facility construction […]
Vancouver, B.C. – March 23, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FRA: 6UF) (“NeonMind”), provides an update from CEO Rob Tessarolo on its research and development activities, as well as its plan to further develop two of its synthetic psilocybin-based drug candidates for the treatment of obesity, compulsive eating disorder and as an […]
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has signed a drug development agreement with Catalent, Inc. (NYSE:CTLT) the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Cybin will be applying Catalent’s […]
Mindset Pharma Announces $5 Million Bought Deal Financing
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset“) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp., as sole bookrunner and lead underwriter (the “Lead Underwriter“) pursuant to which the Lead Underwriter has agreed, on behalf of a syndicate of underwriters (together with the Lead Underwriter, the […]
Novamind to Present at Benzinga Biotech Conference
Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the Benzinga Biotech Small Cap Conference (“the Conference”), a virtual conference taking place on March 25th, 2021. On Thursday, March 25th, at 9:25am EST, Novamind’s CEO and Director, Yaron Conforti, will present the Company’s […]
NEO Exchange Announces Inclusion in FTSE Russell Indexes
NEO is proud to announce that FTSE Russell, the global index, data, and analytics provider, now recognizes the NEO Exchange as an eligible stock exchange for inclusion in FTSE Global Equity indexes. “Tier 1 stock exchanges remain the only exchanges to be included in indexes around the world – yet not every exchange is recognized […]
#CanndoraConnect brings Women in Cannabis and Psychedelics together to learn and inspire
#CanndoraConnect: International Women’s Day on March 8th, 2021 offered attendees a unique experience, providing collaboration, networking, inspiration, and advice for women’s success in the cannabis and emerging psychedelics industry worldwide. The event featured eleven industry professionals and sold out with over 100 registrants from around the world. The event featured notable panelists who shared […]
March 22, 2021 07:15 AM Eastern Daylight Time TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has signed a drug development agreement with Catalent, Inc. (NYSE:CTLT) the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and […]
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (“Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has filed a pre-IND (Investigational New Drug) meeting request with the U.S. FDA for its investigation of AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family, for […]
TORONTO, March 19, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment […]
March 17, 2021 07:15 AM Eastern Daylight Time TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has completed its 20th pre-clinical study and is progressing its CYB003 and CYB004 proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. “Excellent team-work and fully supportive partners […]
KELOWNA, British Columbia, March 18, 2021 (GLOBE NEWSWIRE) — Allied Corp. (“Allied”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted psilocybin and cannabinoid health solutions to address today’s medical issues, is pleased to announce that it has submitted a provisional patent for the Allied therapeutic formulation and treatment regimen involving a prescription […]
Novamind Partners with Merck for New Treatment-Resistant Depression Trial
Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site TORONTO, ON / ACCESSWIRE / March 18, 2021 / Novamind Inc. (CSE: NM, OTC: NVMDF, FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly-owned subsidiary, Cedar Clinical Research (“CCR”) has been selected […]
Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics
La Jolla, California–(Newsfile Corp. – March 18, 2021) – Tryp Therapeutics (CSE: TRYP), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today that it has submitted a provisional patent (US 63/161,070) to improve how psychedelics are administered across a broad range of indications. The provisional patent describes […]
Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal Financing
TORONTO, March 17, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip“), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has closed the bought deal short form prospectus offering previously announced on February 25 and 26, 2021, including the full exercise […]
Toronto, Ontario–(Newsfile Corp. – March 16, 2021) – PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a sponsored […]
Mindset Pharma Announces DTC Eligibility for OTCQB Venture Listing
Toronto, Ontario–(Newsfile Corp. – March 17, 2021) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin-inspired medicines and related technologies, is pleased to announce that it has received confirmation of eligibility from The Depository Trust Company (“DTC“) for electronic settlement […]
Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt
Prof. Nutt appointed Head of Research to Lead Awakn’s Next-Gen Psychedelic Molecule Development Awakn Life Sciences announces the acquisition of significant proprietary research data on next generation candidate MDMA and Ketamine molecules from Prof. David Nutt’s Equasy Enterprises. In addition to the acquisition of the data, Prof. Nutt has been appointed as Head of Research to lead […]
VANCOUVER, BC, March 16, 2021 /PRNewswire/ – Delic Holdings. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce the appointment of John Coleman, PhD, former President of Anandia Labs, as Vice President of Business Development. Matt Stang commented “We are very fortunate to have John join our team. His pedigree between his corporate and […]
Silo Pharma Targets Rheumatoid Arthritis with Latest Deal
Every pathological condition contains disease-specific molecular tags on its vasculature, creating a kind of “zip code” that tells where it’s located in the body. There are peptides, or short chains of amino acids, that home specifically to these pathological conditions and can be used as a highly targeted therapeutic for the delivery of an active […]
Tryp Therapeutics: Monetizing Its PFN™ Program
There are a growing number of publicly traded psychedelics companies for investors to consider for their portfolios but few have been making tangible progress toward the development and commercialization of game-changing therapies. Tryp Therapeutics Inc. (CSE: TRYP) is keenly focused on developing compounds with known safety profiles for the treatment of rare diseases and other […]
Toronto, Ontario–(Newsfile Corp. – March 15, 2021) – Mindset Pharma Inc. (CSE:MSET) (FSE: 9DF) (“Mindset” or the “Company“) is pleased to announce that it has filed a sixth provisional patent application with the United States Patent and Trademark Office. This most recent patent application covers a comprehensive range of novel N,N-Dimethyltryptamine (“DMT“) and 5-methoxy-N,N–dimethyltryptamine (“5-MeO-DMT“) analogs, their related […]
Halucenex is a Psychedelic-Assisted Psychotherapy (PAP) company • Halucenex focuses on the commercialisation and R&D of novel psychedelic molecules for the treatment of Post Traumatic Stress Disorder (PTSD), Depression and other mental illnesses • Agreement provides Creso Pharma with entry into the emerging global market for psychedelics medicines – estimated to be worth […]
Die Psybrary™ von MagicMed ist eine bemerkenswerte und beeindruckende Leistung, die mehr als geschätzten 125 Millionen Derivaten bis zu deren Patenterteilung Patentschutz bieten könnte. Während 125 Millionen Derivate eine große Zahl ist, sollten dabei zwei Dinge klargestellt werden. Erstens bedeutet diese Zahl nicht, dass das Unternehmen eine kleine Armee von Wissenschaftlern weggesperrt hat, um 125 […]
NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity
Vancouver, B.C. – March 11, 2021: NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FRA: 6UF) (“NeonMind”) is pleased to announce that on March 10 2021, NeonMind engaged Certara®, the global leader in model-informed drug development to provide strategic integrated drug development support for the investigation of NeonMind’s psilocybin based drug candidates for the treatment of obesity. […]
VANCOUVER, BC, March 11, 2021 /PRNewswire/ – Delic Holdings. (“DELIC” or the “Company”) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to announce the appointment of Zak Garcia, former CMO of Bulletproof Inc., makers of Bulletproof® Coffee, as Chief Marketing Officer. Matt Stang commented “Zak has been with DELIC on our Board of Advisors since inception, and having […]
The Psybrary™: 12 Choose Your Own Adventure Stories, Millions of Endings
MagicMed’s PsybraryTM is a remarkable and impressive achievement that, pending patent approval, could provide patent protection to more than an estimated 125 million derivatives. While 125 million derivatives is a big number, two clarifications should be made. Firstly, this number does not indicate that they have locked a small army of scientists away to fulfill […]
Delic’s Vision Comes Into Focus With a Flurry of Acquisitions
Investors have many different options when it comes to building exposure into the psychedelics sector within their portfolios. While some companies are undergoing large-scale and years-long clinical trials to prove efficacy, others are opening wellness clinics or cultivating mushrooms in legal jurisdictions. Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) is a relatively new player […]
VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) — Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (FRA: MY0) (the “Company” or “Myconic“) is pleased to announce that the Company has entered into a letter of intent (the “LOI”) for the acquisition of all of the issued and outstanding shares of Mindscape Ketamine & […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
TransCanna™ specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products.
ICC International Cannabis’ corporate mandate is to plan, design, build and operate the highest quality, lowest cost Cannabis production, processing and distribution facilities worldwide.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
